Novavax cuts 2024 revenue forecast
Hosted on MSN7h
Novavax’s stock slides 7% as guidance cut offsets narrower-than-expected third-quarter lossNovavax Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected ...
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
The latest update is out from Novavax ( (NVAX)). Novavax, a leader in vaccine development, announced the FDA’s removal of a clinical hold on their COVID-19-Influenza combination and influenza ...
Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. [Operator Instructions] After ...
Novavax, a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, is proud to announce an exciting new partnership with the Los Angeles Rams aimed at "Protecting the Rams House" ...
FY24 consensus $761.46M. Cuts FY24 product sales view to $175M-$225M from $275M-$375M. Raises FY24 Licensing, Royalties and Other Revenue view ...
GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Tuesday reported a loss of $121.3 million in its third quarter. On a per-share basis, the Gaithersburg, Maryland-based company ...
Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...
Hosted on MSN4h
Novavax Stock Dives Even Though Results Beat ForecastsNovavax stock fell sharply after the pharmaceutical company cut its forecast for annual revenue despite ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback